Cayman Pharma s.r.o

Cayman Pharma is a leading European provider of cGMP prostaglandin APIs, created in 2006 from the merger of Cayman Chemical and NeraPharm, combining deep prostaglandin chemistry expertise. With nearly 60 years of experience, it uses a patented route for the prostaglandin core structure and holds GMP approvals from European and US regulators. The company supports fertility, eye care, glaucoma, and pulmonary hypertension products with validated GMP routes and regulatory support. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.